Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of Jean L. Chan, M.D., as Vice President, Clinical Development, reporting to David T. Hagerty, M.D., Executive Vice President, Clinical Development.

“We are pleased to welcome Jean to the Conatus Clinical Development team,” said Dr. Hagerty. “Her substantial academic accomplishments and registration and approval experience are well-suited to our expanding clinical needs, especially as we advance with our initial registration plans. Her demonstrated ability to successfully lead a drug through the approval process and understanding of the metabolic complications of non-alcoholic fatty liver disease bring important capabilities to Conatus. We look forward to her contributions toward advancing emricasan toward regulatory approval and commercial success.”

Dr. Chan has been Director, Global Clinical Research – CV/Metabolics, at Bristol-Myers Squibb since 2013, and was Medical Director, Medical Research & Development, at Amylin Pharmaceuticals from 2008 until its acquisition by Bristol-Myers Squibb in 2012. Dr. Chan was the lead clinician for the clinical development of metreleptin (MYALEPT™), including the analysis of the registrational studies, BLA filing strategy, and presentation at the FDA Advisory Committee meeting. She previously served in a series of academic appointments at Harvard Medical School, beginning as a Clinical Fellow in Medicine in 1997 and ending as an Assistant Professor of Medicine in 2008. She held concurrent hospital appointments at Beth Israel Deaconess Medical Center as a Research Associate from 2003 to 2004 and as a Staff Physician from 2004 to 2008, while serving as Attending Physician for the Endocrinology, Diabetes, and Metabolism Clinic and for the Inpatient Endocrinology, Diabetes, and Metabolism Service. Dr. Chan received a M.M.S. in Clinical Investigation from Harvard Medical School, an M.D. from Johns Hopkins University School of Medicine, an M.S. in Computer Science from Johns Hopkins University, and a B.S. in Computer Science from Johns Hopkins University. She is Board Certified in internal medicine, and endocrinology, diabetes and metabolism. (Original Source)

Shares of Conatus Pharmaceuticals closed last Friday at $5.61 . CNAT has a 1-year high of $11.74 and a 1-year low of $5.13. The stock’s 50-day moving average is $5.83 and its 200-day moving average is $6.46.

On the ratings front, Conatus Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on April 27, MLV & Co. analyst Vernon Bernardino maintained a Buy rating on CNAT, with a price target of $16, which implies an upside of 185.2% from current levels. Separately, on the same day, Brean Murray Carret’s Difei Yang initiated coverage with a Buy rating on the stock and has a price target of $13.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Difei Yang have a total average return of -2.0% and 20.3% respectively. Bernardino has a success rate of 47.4% and is ranked #3088 out of 3612 analysts, while Yang has a success rate of 71.7% and is ranked #232.

In total, 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $12.00 which is 113.9% above where the stock closed last Friday.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.